A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks
This study will explore the combination of the oral drug PF-00299804 and intravenous CP-751,871 in patients with advanced solid tumor. Each of these drugs have been given separately to patients in prior studies, and this study is to establish the safety and efficacy of the combination.
Carcinoma, Non-Small Cell|Neoplasm Metastasis
DRUG: PF-00299804
Overall safety profile characterized by type, frequency, severity (as graded using NCI CTC AE v. 3.0), timing, seriousness and relationship to trial treatment of adverse events and laboratory abnormalities., 18 months
Plasma Pharmacokinetic Parameters of PF-00299804 and CP-751,871, 12 months|Progression Free Survival (PFS), 15 months|Best overall response (OR) defined according to RECIST guidelines., 12 months|Duration of response (DR), 15 months|Anti-Drug Antibodies (ADA) response;, 18 months|KRAS mutation and EGFR gene amplification and mutation status in available NSCLC tumor tissue (fresh or archived) (NSCLC MTD Expansion Cohort, 12 months
This study will explore the combination of the oral drug PF-00299804 and intravenous CP-751,871 in patients with advanced solid tumor. Each of these drugs have been given separately to patients in prior studies, and this study is to establish the safety and efficacy of the combination.